Drug Profile
IBPB 002IB
Alternative Names: IBPB002IB; IBPB002IB (biosimilar) - Inbiopro SolutionsLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Inbiopro Solutions
- Class Antivirals; Proteins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Multiple sclerosis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Multiple-sclerosis in India (Parenteral)
- 31 Dec 2011 Clinical trials in Multiple sclerosis in India (unspecified route)